Aurobindo receives USFDA Approval for Cefpodoxime proxetil Tablets

Aurobindo Pharma Ltd has announced that the USFDA has approved one more from its cephalosporin stable and again from its third generation breed. Cefpodoxime proxetil Tablets in the strengths of 100mg and 200mg has been approved. This is the 7th cephalosporin approval for the Company. With this the Company consolidates itself further in cephalosporin market. Cefpodoxime is the generic version of Pharmacia Upjohn's Vantin.

Cefpodoxime Proxetil is mostly used to treat Acute otitis media, community acquired Pneumoniae, Uncomlicated Urinary tract Infections and also skin infections.

The Company is the proven leader in this segment / product range in several markets in the world. This would be a niche opportunity for the Company as there are limited number of players in the segment.

USFDA has also confirmed its approval for Cefpodoxime proxetil for oral suspension in the strengths of 50mg/5ml and 100mg/5ml.

The stock was trading at Rs.753, up by Rs.0.85 or 0.11%. The stock hit an intraday high of Rs.764 and low of Rs.749. The total traded quantity was 38406 compared to 2 week average of 220958.

Source : Equity Bulls

Keywords